On the 10th, NeoPharm's ZEROID announced its strategic enhancement in product effectiveness through rigorous research, responding to shifting consumer preferences in the dermocosmetics market. With a growing emphasis on functional ingredients and proven efficacy backing, the brand focuses on reinforcing skin barrier technologies that appeal to both medical professionals and mainstream consumers.

This evolving marketplace recognizes a surge in dermocosmetics catering to skin barrier repair and soothing properties. As brands traditionally found in clinics broaden their reach into popular retail channels like Olive Young, the once distinct boundary separating dermocosmetics from conventional skincare products continues to blur, prompting a shift in evaluation criteria toward efficacy validation.

By leveraging foundational research on skin barrier technologies, ZEROID is well-positioned to capitalize on this trend. Their proprietary MLE® technology creates an environment akin to natural skin while incorporating defensive agents such as Defensamide to improve the overall condition of compromised skin. This formulation strategy not only aligns with current consumer demands but also strengthens their technological differentiation in a competitive landscape.

Further corroborating its research-driven approach, ZEROID collaborates with dermatologists to ensure clinical efficacy. Their joint research revealed that patients using ZEROID Intensive Rich Cream alongside steroid treatments experienced notable improvements in dry and itchy skin conditions. This study was published in the international SCI journal 'Dermatology and Therapy,' providing objective validation of their product claims.

ZEROID’s commitment to scientific integrity is further underscored by its status as the first Korean brand to receive medical device registration for the ZEROID MD product line. This positions the brand favorably in the domain of medical skincare, largely prescribed and recommended in clinical settings, thereby enhancing its credibility and market presence.